Analysis
Analysis
Lilly's $40M Absci deal: what the price signals, and what it doesn't
Absci sold $100M of stock at its $7.41 last sale price, with Eli Lilly taking $40M. The filings disclose no rights for Lilly, so the signal has limits.
Analysis: opinion, not investment advice
Biotech companies rarely sell stock at the market price. Absci (ABSI) did in June, with one large buyer in the book. The AI-led antibody designer sold 13,495,277 shares at $7.41, the same as its last reported sale price on June 23rd, for $100m. Eli Lilly was allocated 5,398,111 of those shares, or $40m. Our news desk reported the deal and the cash it added. This piece asks what Lilly's cheque buys.
The terms
The prospectus supplement is plain. The price was $7.41, the underwriting discount $0.4446 a share, or 6%, and net proceeds about $93.5m. Jefferies, J.P. Morgan Securities, TD Securities (USA) and Guggenheim Securities were the representatives of the underwriters and book-running managers. After the sale Absci expected 168,845,412 shares outstanding. The money goes to ABS-201, an AI-designed antibody against the prolactin receptor, in hair loss and endometriosis.
On the same day Absci published interim phase 1 data for ABS-201 in 32 healthy volunteers: no serious adverse events at the data cutoff and an estimated half-life of at least 65 days, which supports dosing two or three times in six months. Interim proof-of-concept data in hair loss are due in the second half of 2026.
How rare a zero discount is
Compare two later deals. Recursion Pharmaceuticals (RXRX), another AI-native developer, sold $200m of stock in October at $3.25, about 13% below its $3.74 last sale, with no strategic anchor. Viking Therapeutics (VKTX) sold 7,857,143 shares at $35.00 in September, against a last reported sale price of $40.85 on September 22nd in its prospectus, about 14% below by our arithmetic, after strong obesity data. Absci, with early safety data and a smaller market value than either, sold at its last reported sale price and paid the bankers' 6%.
One plausible explanation, ours rather than the company's, is the 40% of the book that Lilly took. A large pharma buyer reduces how much stock the bankers must place with hedge funds that want a discount, and signals scientific interest to everyone else.
What Lilly gets
Here the filings are quiet. The prospectus mentions Lilly once, as a buyer of $40m of shares. The 8-K filed with the underwriting agreement, the data release and the second-quarter 10-Q disclose no board seat, option, right of first negotiation or commercial agreement tied to the stake; the 10-Q does not mention Lilly at all. We found no Schedule 13G from Lilly. That is consistent with the size: 5.4m shares is about 3.2% of the shares outstanding after the deal by our arithmetic, below the 5% level that triggers a 13G, unless Lilly held shares before, which the filings do not say.
So, on the public record, Lilly bought stock on the same terms as everyone else. That is good for other shareholders, because the filings show no extra terms for Lilly. It also makes the signal weaker than the headline suggests. A $40m equity position is a modest sum for Lilly and carries no obligation to partner on ABS-201.
The criticism
The board, chaired by Frans van Houten since April 2024, and management under chief executive Sean McClain and chief financial officer Zachariah Jonasson (who signs the 10-Q) got the stock away at its last sale price. They face questions on two points.
First, disclosure. When a single strategic investor anchors 40% of a raise, shareholders are entitled to a clear statement of whether any side arrangement exists. The filings imply there is none; a sentence saying so would have cost nothing.
Second, concentration of the story. Absci's equity case now leans on ABS-201 and, by association, on the perception that Lilly is interested in it. If the hair-loss proof-of-concept disappoints, the stock has no contractual partner to fall back on. The prospectus also flags that lock-ups for officers and directors include an exception for sales to cover taxes on option exercises and vesting, which it says could weigh on the share price.
What to watch
The interim efficacy readout in hair loss, the start of the endometriosis phase 2, and any filing in which Lilly's role grows beyond that of a shareholder. In June Absci sold stock at its last sale price with a strategic buyer taking 40%. The next raise will show what price the data command without one.
Sources: 424B5 dated June 24th 2026, 8-Ks of June 24th, ABS-201 data release, Q2 10-Q, 2026 proxy, all linked above. Auditor: Ernst & Young LLP, per the 2026 proxy.
Sources
- 13,495,277 shares at $7.41
- published interim phase 1 data
- 13% below its $3.74 last sale
- 8-K filed with the underwriting agreement
- second-quarter 10-Q
- since April 2024
Disclosures
- Every figure carries the as-of date of its source.
- This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
- Our method and conflicts policy: aibio.space/disclosures/
As of , aibio.space has received no compensation from, and has no paid relationship with, the company covered.
Investor Chat
Loading posts…
aibio